Medroxyprogesterone

Catalog No.S3635 Batch:S363501

Print

Technical Data

Formula

C22H32O3
Molecular Weight 344.49 CAS No. 520-85-4
Solubility (25°C)* In vitro DMSO 68 mg/mL (197.39 mM)
Ethanol 14 mg/mL (40.63 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Medroxyprogesterone (MP) is a synthetic pregnane steroid and a derivative of progesterone. It is a potent progesterone receptor agonist.
In vitro Medroxyprogesterone acetate (MPA, 10 nM) treatment for 48 h induces proliferation of the cells (1.6-fold induction). MPA induces cyclin D1 expression (3.3-fold induction). MPA increases both the protein level (2.2-fold induction) and promoter activity (2.7-fold induction) of cyclin D1 in MCF-7 cells transfected with PRB but not with PRA. Although MPA transcriptionally activates cyclin D1 expression, cyclin D1 promoter does not have progesterone-responsive element-related sequence. MPA induces the transient phosphorylation of Akt (2.7-fold induction at 5 min) and also phosphorylation of inhibitor of NFkappaBalpha (IkappaBalpha) (2.3-fold induction)[1]. MPA activates glucocorticoid receptors, which could mimic part of the anti-atherosclerotic effects of glucocorticoids, and has, on the other hand, also anti-androgenic activity, which might diminish protective oestrogen effects[2].
In vivo Long-term treatment with MPA and MPA + E2 increases arterial thrombosis despite inhibitory effects of MPA on atherosclerosis in ApoE-deficient mice. Increased thrombin formation, reduced smooth muscle content and remodelling of non-collagenous plaque matrix may be involved in the pro-thrombotic effects. Thus, MPA exhibits differential effects on arterial thrombosis and on atherosclerosis. In monkeys, MPA interferes with anti-atherosclerotic oestrogen effects whereas progesterone does not[2].

Protocol (from reference)

Cell Assay:[1]
  • Cell lines

    T47D human breast cancer cells

  • Concentrations

    10 nM

  • Incubation Time

    4 days

  • Method

    The cells are plated at a density of 10 or 40 × 104 cells/well in 12-well plates and allowed to attach overnight. The cells are then growth arrested by incubation in phenol red-free DMEM with 10% charcoal-stripped serum for 24 h followed by treatment with vehicle or MPA by exchanging the culture medium containing these agents with fresh medium every 24 h for 4 d. A Neubauer chamber is used to count cells, and trypan blue experiments are carried out in quadruplicate.

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.